- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | FEMASYS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 18.04. | Femasys Inc.: Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives | 3 | GlobeNewswire (USA) | ||
| 05.04. | FEMASYS INC - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 28.03. | FEMASYS INC - 10-K, Annual Report | 2 | SEC Filings | ||
| 28.03. | Femasys GAAP EPS of -$0.93, revenue of $1.07M | 3 | Seeking Alpha | ||
| 28.03. | FEMASYS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 28.03. | Femasys Inc.: Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update | 62 | GlobeNewswire (Europe) | ATLANTA, March 28, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office... ► Artikel lesen | |
| 21.03. | Femasys Inc.: Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape | 4 | GlobeNewswire (USA) | ||
| 20.03. | Jones Trading raises Femasys shares PT to $10, cites 'topline' study results | 4 | Investing.com | ||
| 20.03. | Femasys Announces Positive Data For FemaSeed Trial To Enhance Fertilization In Women | 3 | RTTNews | ||
| 20.03. | Femasys Inc.: Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed for the Treatment of Infertility | 636 | GlobeNewswire (Europe) | -- In the severe male factor cohort, findings show 24% of women became pregnant after FemaSeed -- -- FemaSeed pregnancy rate by cycle was more than double historic intrauterine insemination (IUI)... ► Artikel lesen | |
| 20.03. | FEMASYS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 06.03. | FEMASYS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 06.03. | Femasys Inc.: Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution | 392 | GlobeNewswire (Europe) | -- Paving the way forward for the broader commercial availability of FemaSeed, an accessible, safe, and cost effective alternative to IVF -- -- Ongoing uncertainty following recent Alabama Supreme... ► Artikel lesen | |
| 28.02. | FEMASYS INC - 8-K, Current Report | 2 | SEC Filings | ||
| 28.02. | Femasys Inc.: Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF | 266 | GlobeNewswire (Europe) | -- Femasys readies for the commercial launch of FemaSeed® in the U.S. amidst the uncertainty following the Alabama Supreme Court Ruling on how to handle embryos used for in vitro fertilization (IVF)... ► Artikel lesen | |
| 06.02. | Femasys appoints Richard Spector as new CCO | 2 | Investing.com | ||
| 06.02. | FEMASYS INC - 8-K, Current Report | 2 | SEC Filings | ||
| 06.02. | Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer | 243 | GlobeNewswire (Europe) | -- Seasoned sales and marketing executive with 25 years of experience leading public and private healthcare companies throughout various stages of commercialization will lead commercial launch of... ► Artikel lesen | |
| 26.01. | Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women | 2 | GlobeNewswire (USA) |
Seite:
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTUITIVE SURGICAL | 350,65 | +0,06 % | Quartalszahlen: China sei Dank: Intuitive Surgical übertrifft Erwartungen, Aktie steigt! | © Foto: Frank Molter - picture allianceDie Aktie des Herstellers von Medizinrobotern Intuitive Surgical ist nach guten Quartalszahlen gefragt und steigt.Erholung in China ließ lange auf sich warten... ► Artikel lesen | |
| ROKU | 57,88 | +0,17 % | Qurate Launches 'The Big Dish' on The Roku Channel | ||
| ATOSSA THERAPEUTICS | 1,446 | +2,70 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen | SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company") today announced promising safety and efficacy data from the Company's Phase 2 EVANGELINE... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 | -- Third Consecutive Year of Phexxi Net Sales Growth --
-- Total Operating Expense Reduced 64% from 2022 Levels --
-- Sales and marketing expense as a percentage of net sales was 54% for the fourth... ► Artikel lesen | |
| ORPEA | 12,338 | -0,93 % | EMEIS PURSUES ITS REFOUNDATION: 2023 Consolidated Financial Results of ORPEA S.A. | Significant improvement in non-financial indicators, with major advances for employees, residents and patients
Health and safety: decline in the work-related accident frequency rate, at 24.8... ► Artikel lesen | |
| QUIDELORTHO | 36,600 | -4,19 % | QuidelOrtho Reports Fourth Quarter and Full-Year 2023 Financial Results | SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care... ► Artikel lesen | |
| VERU | 1,220 | -1,45 % | LI, VERU and MRIN among pre-market losers | ||
| TEMPEST THERAPEUTICS | 3,328 | +3,81 % | Tempest Therapeutics: Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications | TPST-1120, a first-in-class, oral, selective PPAR? antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancersBased on subsequent positive randomized data... ► Artikel lesen | |
| CENTENE | 70,56 | -0,91 % | Centene-Aktie legt um 0,84 Prozent zu (71,0929 €) | Im Plus liegt aktuell das Wertpapier von Centene . Das Papier kostete zuletzt 75,78 US-Dollar. Heute hat sich an der US-amerikanischen Börse die Centene-Aktie zwischenzeitlich um 0,84 Prozent verteuert.... ► Artikel lesen | |
| NANO-X IMAGING | 9,100 | 0,00 % | Nano-X Imaging Ltd. - 6-K, Report of foreign issuer | ||
| PERSPECTIVE THERAPEUTICS | 1,630 | +5,16 % | Perspective Therapeutics, Inc.: Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results | SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout... ► Artikel lesen | |
| LANTHEUS | 60,10 | -1,35 % | Lantheus Holdings, Inc.: Lantheus to Host First Quarter 2024 Earnings Conference Call and Webcast on May 2, 2024, at 8:00 a.m. Eastern Time | ||
| AMN HEALTHCARE SERVICES | 52,50 | 0,00 % | AMN Healthcare Services Inc: Survey: Physicians Turning to Locum Tenens to Improve Work Conditions, Relieve Burnout | ||
| OMNICELL | 26,200 | +1,55 % | Omnicell Announces Fiscal Year and Fourth Quarter 2023 Results | FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy care delivery model, today... ► Artikel lesen | |
| BUTTERFLY NETWORK | 0,707 | 0,00 % | ThinkSono Ltd: ThinkSono Releases Real-Time DVT AI Training Solution for Butterfly Network's Handheld Ultrasound Devices | LONDON, ENGLAND / ACCESSWIRE / April 23, 2024 / ThinkSono, a pioneering provider of AI-driven medical imaging solutions, is proud to announce the release of ThinkSono AI Training, a deep vein thrombosis... ► Artikel lesen |
Das Unternehmen FEMASYS INC kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,330 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
